To Hold or Not to Hold, that is the Newest Sodium-Glucose Cotransporter-2 Inhibitor Question
Open Access
- 28 August 2025
- journal article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1254-1255
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary AngiographyKidney360, 2025
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024Diabetes Care, 2023
- Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular diseaseCMAJ Open, 2023
- SGLT-2 Inhibitors in Heart Failure: A Review of Current EvidenceInternational Journal of Heart Failure, 2023
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary AngiographyJAMA, 2022
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Role of Hydration in Contrast-Induced Nephropathy in Patients Who Underwent Primary Percutaneous Coronary InterventionThe American Journal of Cardiology, 2015
- Predictors for contrast media-induced nephropathy and long-term survival: Prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trialCanadian Journal of Cardiology, 2008
- A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary interventionJACC, 2004